Article

Glaxo Agrees to Pay $3 Billion in Fraud Settlement

GlaxoSmithKline

In the largest settlement involving a pharmaceutical company, the British drugmaker agreed to plead guilty to criminal charges and pay $3 billion in fines for promoting its best-selling antidepressants for unapproved uses and failing to report safety data about a top diabetes drug, federal prosecutors announced Monday. The agreement also includes civil penalties for improper marketing of a half-dozen other drugs.

Paxil

A

vandia

The fine against GlaxoSmithKline over , Wellbutrin, and the other drugs makes this year a record for money recovered by the federal government under its so-called whistle-blower law, according to a group that tracks such numbers.

Read the full story: http://tinyurl.com/7stfqlx

Source: The New York Times

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Marry Vuong, PharmD, BCPPS
Dr Elise Tremblay
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo